Evidence supporting the use of INTERCEPT continues to grow with
multiple presentations and abstracts at ISBT
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced results of 16 abstracts
presenting experiences with the INTERCEPT Blood System for platelets,
plasma, and red blood cells during the 27th Regional Congress
of the International Society of Blood Transfusion (ISBT) in Copenhagen,
Denmark held from June 17 to June 21, 2017. ISBT is one of
the premier congresses in blood transfusion science and medicine.
“These studies continue to build the body of evidence demonstrating
robust pathogen inactivation performance across the full portfolio of
INTERCEPT treated blood components,” noted Dr. Richard Benjamin, Cerus'
chief medical officer. “In addition, data presented at ISBT support the
European launch of our triple storage container platelet set, showing
comparable performance to existing sets while improving economics and
operational efficiencies. Data on INTERCEPT red cells continues to
demonstrate strong product performance and potentially provides the
opportunity to replace gamma irradiation and red cell washing. Lastly,
pathogen inactivated cryoprecipitate plasma addresses an important unmet
clinical need to correct for fibrinogen deficit in surgery, trauma, and
maternal hemorrhage.”
Key presentations of interest include:
-
Pathogen Inactivation of Zika, Dengue, and Chikungunya Viruses
In All Blood Components, by D Musso, F Santa Maria, A Laughhunn et
al: New data combined with previous published studies show that
INTERCEPT inactivates Zika, Dengue, and Chikungunya viruses to the
limit of detection in plasma, platelet, and red blood cell components.
-
Storage Study of Apheresis Platelets In Additive Solution After
Photochemical Treating Using a Novel Triple Storage Set, by A
Lotents, N de Valensart, S Acqart, F Cognasse, T Najdovski, A Rapaille:
Apheresis platelets collected and stored with the triple set compared
to the single set showed no significant difference in in vitro
platelet function after INTERCEPT treatment for up to seven days of
storage.
-
Evaluation of Pathogen Reduced (Amotosalen-UVA) Pooled
Cryoprecipitate and Cryoprecipitate-Poor Plasma, by L Amorim, T
Ferreira, J Oliveira, F Azevedo, A Oliveira, M Lopes: For patients
in need of cryoprecipitate and cryoprecipitate-poor plasma, pathogen
inactivation improves both safety and availability. In addition, the
authors make the case for the system to improve overall
cryoprecipitate production at a lower cost.
-
Robustness of the INTERCEPT Blood System for Red Blood Cells,
by A Erickson, M Schott, B Warbington, G Villegas, D Hanson, N Mufti:
Red blood cell units treated with pathogen inactivation met the
European Directorate for the Quality of Medicines & Healthcare (EDQM)
guidelines with respect to hematocrit, hemoglobin content and
hemolysis at end of storage.
-
Implementation of double dose pathogen-inactivated
platelets in routine with productivity and cost optimization,
by MB S. Madsen: By replacing gamma irradiation and bacterial
detection, converting to production of double-dose buffy coat
platelets, and replacing automated platelet production with manual
processing, the Blood Center of the Aalborg University Hospital has
demonstrated the ability to produce INTERCEPT platelets with a 13%
reduction in cost compared to their prior conventional platelet supply.
A full list of abstracts can be viewed at www.cerus.com/Events/news-and-events/ISBT-Copenhagen/.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for information about Cerus.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170621005444/en/
Source: Cerus Corporation